BIT225 perhaps had some commercial aspects, assuming it also had...

BIT225 perhaps had some commercial aspects, assuming it also had some potency levels against some other diseases worth trialing

But unfortunately the recent results of various assays showed no (not one) screening hits.. and BIT continue to fail at disclosing these results which are price sensitive! Credibility Zero and a 'continuous disclosure' failure

This dramatically reduces the commercial strength of the compound, and I can imagine drops BIT225 from big Pharma's priority lists and interest radar

C19 has always just been a distraction...

HIV vaccines are in development and as can be seen with C19, are improving with time to market (TTM) in comparison to therapeutics. Vaccines are generally cheaper to develop and their commercial strength appears to be rapidly increasing (in comparison to therapeutics) as time goes on, as technology improves and Pharma improve their in-house capabilities

Perhaps BIT should look at vaccines, or cancers where therapeutics can really flex their muscles imo...the avenue which BIT have perused over the last 20 years have drawn considerable capital for zilch return for shareholders

BIT seemed to have failed at adapting to the commercial environment